发布求助
文献互助 智能选刊 最新文献

International journal of immunotherapy and cancer research最新文献

筛选
英文 中文
Immunogenicity in CAR T cell immunotherapy CAR - T细胞免疫治疗的免疫原性
International journal of immunotherapy and cancer research Pub Date : 2023-10-04 DOI: 10.17352/2455-8591.000038
Yu Emily
{"title":"Immunogenicity in CAR T cell immunotherapy","authors":"Yu Emily","doi":"10.17352/2455-8591.000038","DOIUrl":"https://doi.org/10.17352/2455-8591.000038","url":null,"abstract":"Currently, the most accessible forms of cancer treatment include surgery, chemotherapy, and radiation. However, these forms of treatment may damage or destroy healthy tissue as well as cancerous cells, resulting in side effects such as fatigue, hair loss, diarrhea, etc. Immunotherapy, an alternative form of cancer treatment, is a growing treatment method of interest that uses bodily substances made by the body or in a laboratory to boost the immune system’s activity against tumor cells. One type of immunotherapy is CAR T cell therapy, in which a patient’s T cells are genetically modified in a lab to express Chimeric Antigen Receptors (CARs) that help T cells identify and destroy their target. However, because CARs are constructed in the lab and currently consist of non-self components, genetically engineered CAR T cells have the potential to induce anti-CAR immune responses. The following paper will explore the causes of anti-CAR immunity, its possible solutions, and the potential implications of these discoveries.","PeriodicalId":91288,"journal":{"name":"International journal of immunotherapy and cancer research","volume":"4 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135647521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The potential of mRNA vaccine in HCC treatment mRNA疫苗在HCC治疗中的潜力
International journal of immunotherapy and cancer research Pub Date : 2023-07-11 DOI: 10.17352/2455-8591.000037
H. Rui
{"title":"The potential of mRNA vaccine in HCC treatment","authors":"H. Rui","doi":"10.17352/2455-8591.000037","DOIUrl":"https://doi.org/10.17352/2455-8591.000037","url":null,"abstract":"Neoantigen mRNA vaccines are a potential form of immunotherapy for Hepatocellular Carcinoma (HCC). These neoantigens can be targeted with personalized mRNA vaccines, which are designed to stimulate the patient’s immune system to recognize and destroy cancer cells. Neoantigen mRNA vaccines are developed using RNA sequences that are synthesized based on the genetic mutations found in HCC patients. These RNA sequences are formulated into a vaccine and administered to the patient, typically in combination with other cancer treatments for enhancing the anti-cancer effect. Several preclinical and clinical studies have shown promising results for neoantigen mRNA vaccines in HCC immunotherapy. Early results suggest that they may be a valuable addition to the treatment options available for HCC patients. However, more research is needed to determine the safety and efficacy of these vaccines.","PeriodicalId":91288,"journal":{"name":"International journal of immunotherapy and cancer research","volume":"51 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81362427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current understanding of the cardiotoxicity-related treatment of immune checkpoint inhibitors in breast cancer 目前对乳腺癌免疫检查点抑制剂心脏毒性相关治疗的了解
International journal of immunotherapy and cancer research Pub Date : 2023-05-03 DOI: 10.17352/2455-8591.000036
Dai Jiajing
{"title":"Current understanding of the cardiotoxicity-related treatment of immune checkpoint inhibitors in breast cancer","authors":"Dai Jiajing","doi":"10.17352/2455-8591.000036","DOIUrl":"https://doi.org/10.17352/2455-8591.000036","url":null,"abstract":"Immune Checkpoint Inhibitors (ICIs) as the most important and widely used currently, have changed the traditional approach to cancer treatment and significantly improved the prognosis of most patients with advanced malignancies. Breast cancer is the most dangerous threatening tumor to women’s health and life globally, ICIs have shed light on the treatment for refractory breast cancer subtypes, including Triple-Negative Breast Cancer (TNBC) and trastuzumab resistance of human epidermal growth factor receptor 2 positives (HER2+). However, immune-related adverse events (irAE) associated with ICIs bring many extra considerations. Among these, potential cardiotoxicity is rarely seen but with the highest fatality rate. In the present review, we introduced the ICIs approved for the treatment of breast cancer and brief guideline for clinical application. Then we briefly summarized ICIs-related cardiotoxicity in breast cancer and mechanism based on immunology and basic medical research. Furthermore, we make a brief summary of the diagnosis methods.","PeriodicalId":91288,"journal":{"name":"International journal of immunotherapy and cancer research","volume":"64 4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86451091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CNS-invasive aspergillosis following ibrutinib therapy 伊鲁替尼治疗后的中枢侵入性曲霉病
International journal of immunotherapy and cancer research Pub Date : 2022-12-08 DOI: 10.17352/2455-8591.000035
Kurian Matthew, Vick Eric, Khanapara Dipen
{"title":"CNS-invasive aspergillosis following ibrutinib therapy","authors":"Kurian Matthew, Vick Eric, Khanapara Dipen","doi":"10.17352/2455-8591.000035","DOIUrl":"https://doi.org/10.17352/2455-8591.000035","url":null,"abstract":"Ibrutinib is Bruton’s tyrosine kinase inhibitor that now become the standard of care for the treatment of CLL (chronic lymphocytic leukemia) and other lymphoid cancers. With its increasing usage, oncologists must become more aware of their potential side effect profile. Ibrutinib is typically thought to be less immunosuppressive than standard immunotherapy; however, can still cause devastating side effects. We present a case of CNS-invasive aspergillosis in a patient with Waldenstrom’s macroglobulinemia being managed with ibrutinib. We hypothesize that treatment with ibrutinib can resemble those with X-gammaglobulinemia, thus putting our patient at risk of developing such an invasive fungal infection. Traditional risk factors for CNS-invasive aspergillosis include neutropenia, systemic glucocorticoid treatment, mastoidectomy, spinal anesthesia and paraspinal glucocorticoid injections. Oncologists need to weigh the risks and benefits of ibrutinib therapy in certain populations and more data in the future may suggest potentially adding empiric antifungal coverage with its usage.","PeriodicalId":91288,"journal":{"name":"International journal of immunotherapy and cancer research","volume":"54 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86506575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Supposition about absence of contact inhibition of cancer cells 关于癌细胞接触抑制缺失的假设
International journal of immunotherapy and cancer research Pub Date : 2021-11-06 DOI: 10.17352/2455-8591.000034
G. Gogichadze, T. Gogichadze, E. Mchedlishvili
{"title":"Supposition about absence of contact inhibition of cancer cells","authors":"G. Gogichadze, T. Gogichadze, E. Mchedlishvili","doi":"10.17352/2455-8591.000034","DOIUrl":"https://doi.org/10.17352/2455-8591.000034","url":null,"abstract":"As is known, the superficial charge of most somatic cells is negative. Proceeding from this fact, somatic cells never interact. There is always some type of space (intercellular space) between them. Intercellular contacts are predominantly determined by two main factors: Van der Waals (positive taxis) and electrostatic (negative taxis) forces contributing to the formation of membrane electric potential. Presence of the intercellular space is a structural representation of the balance bet­ween these forces (contact inhibition).","PeriodicalId":91288,"journal":{"name":"International journal of immunotherapy and cancer research","volume":"75 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74875959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A case of denosumab-associated hyperparathyroidism: A differential diagnostic challenge denosumab相关性甲状旁腺功能亢进1例:鉴别诊断的挑战
International journal of immunotherapy and cancer research Pub Date : 2021-10-08 DOI: 10.17352/2455-8591.000033
Taşkıran Emin, Şahin Sevnaz, Savaş Sumru, Saraç Zeliha Fulden, Akçiçek Selahattin Fehmi
{"title":"A case of denosumab-associated hyperparathyroidism: A differential diagnostic challenge","authors":"Taşkıran Emin, Şahin Sevnaz, Savaş Sumru, Saraç Zeliha Fulden, Akçiçek Selahattin Fehmi","doi":"10.17352/2455-8591.000033","DOIUrl":"https://doi.org/10.17352/2455-8591.000033","url":null,"abstract":"Denosumab is a relatively new medicine that has become the second option in the treatment of biphosphonate-resistant or intolerant osteoporosis. Subcutaneous injection with 6-month intervals, approval of its usage in stage 3-4 CKD and not having gastrointestinal side effects are advantages of denosumab. However, it has some disadvantages like requiring monitoring serum levels of calcium and vitamin D before each injection.","PeriodicalId":91288,"journal":{"name":"International journal of immunotherapy and cancer research","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86334303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Lymphoepithelioma like Carcinoma of the Bladder – “A Case” Revisited 淋巴上皮瘤样膀胱癌——“一例”再谈
International journal of immunotherapy and cancer research Pub Date : 2020-09-14 DOI: 10.17352/2455-8591.000025
Raleng Mezhuneituo, Aggarwal Gaurav, Gupta Sujoy
{"title":"Lymphoepithelioma like Carcinoma of the Bladder – “A Case” Revisited","authors":"Raleng Mezhuneituo, Aggarwal Gaurav, Gupta Sujoy","doi":"10.17352/2455-8591.000025","DOIUrl":"https://doi.org/10.17352/2455-8591.000025","url":null,"abstract":"Lymphoepitheliomas are a type of undifferentiated carcinomas primarily described in the nasopharyngeal cavity.","PeriodicalId":91288,"journal":{"name":"International journal of immunotherapy and cancer research","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90142877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Significance of Cancer Stem Cells in Anti-Cancer Therapies 肿瘤干细胞在抗癌治疗中的意义
International journal of immunotherapy and cancer research Pub Date : 2016-12-31 DOI: 10.17352/2455-8591.000010
M. Botelho, H. Alves
{"title":"Significance of Cancer Stem Cells in Anti-Cancer Therapies","authors":"M. Botelho, H. Alves","doi":"10.17352/2455-8591.000010","DOIUrl":"https://doi.org/10.17352/2455-8591.000010","url":null,"abstract":"Stem cells are the focus of cutting edge research interest because of their competence both to self-renew and proliferate, and to differentiate into a variety of tissues, offering enticing prospects of growing replacement organs in vitro, among other possible therapeutic implications. It is conceivable that cancer stem cells share a number of biological hallmarks that are different from their normal-tissue counterparts and that these might be taken advantage of for therapeutic benefits. In this review we discuss the significance of cancer stem cells in diagnosis and prognosis of cancer as well as in the development of new strategies for anti-cancer drug design.","PeriodicalId":91288,"journal":{"name":"International journal of immunotherapy and cancer research","volume":"67 1","pages":"14 - 16"},"PeriodicalIF":0.0,"publicationDate":"2016-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89062548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Endothelial Progenitor Cells in Breast Cancer. 乳腺癌中的内皮祖细胞。
International journal of immunotherapy and cancer research Pub Date : 2016-01-23 DOI: 10.17352/2455-8591.000007
M. Botelho, H. Alves
{"title":"Endothelial Progenitor Cells in Breast Cancer.","authors":"M. Botelho, H. Alves","doi":"10.17352/2455-8591.000007","DOIUrl":"https://doi.org/10.17352/2455-8591.000007","url":null,"abstract":"Recent evidences demonstrated the importance of bone marrow derived Endothelial Progenitor Cells (EPC), in the contribution to postnatal physiological and pathological neovascularization, and in tumor growth and angiogenesis. These cells are recruited undifferentiated, in response to systemic or chemoatractive signals, such as Vascular Endothelial Growth Factor (VEGF), they lodge in the growing or lesioned tissue and differentiate into endothelial cells in response to local stimuli and cell-cell interactions. The extent and the significance of the EPCs contribution for the growing of most tumors, including those of the breast, are still not fully defined. We analyzed the peripheral blood of breast cancer patients and found that they have circulating EPCs. We also found an association between expression of AC133+Kdr+ and VEGF plasma levels in these patients. Strategies to impair the mobilization and incorporation of EPCs into breast tumors may contribute to halt the growth of these tumors.","PeriodicalId":91288,"journal":{"name":"International journal of immunotherapy and cancer research","volume":"31 1","pages":"1-2"},"PeriodicalIF":0.0,"publicationDate":"2016-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75375806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 11
Significance of Cancer Stem Cells in Anti-Cancer Therapies. 肿瘤干细胞在抗癌治疗中的意义。
International journal of immunotherapy and cancer research Pub Date : 2016-01-01 Epub Date: 2016-12-31
Mónica Botelho, Helena Alves
{"title":"Significance of Cancer Stem Cells in Anti-Cancer Therapies.","authors":"Mónica Botelho, Helena Alves","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Stem cells are the focus of cutting edge research interest because of their competence both to self-renew and proliferate, and to differentiate into a variety of tissues, offering enticing prospects of growing replacement organs in vitro, among other possible therapeutic implications. It is conceivable that cancer stem cells share a number of biological hallmarks that are different from their normal-tissue counterparts and that these might be taken advantage of for therapeutic benefits. In this review we discuss the significance of cancer stem cells in diagnosis and prognosis of cancer as well as in the development of new strategies for anti-cancer drug design.</p>","PeriodicalId":91288,"journal":{"name":"International journal of immunotherapy and cancer research","volume":"2 1","pages":"14-16"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5298826/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89720993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信